ArriVent BioPharma Inc. Company Profile
NASDAQ: AVBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ArriVent BioPharma at a glance
ArriVent BioPharma Inc. (NASDAQ: AVBP) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Newtown Square, PA. ArriVent BioPharma is led by Dr. Zhengbin Yao Ph.D. and employs about 77 people. The company's shares have traded publicly since 2024.
At a market capitalization of $544.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001868279, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does ArriVent BioPharma do?
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- ArriVent BioPharma Inc.
- Ticker
- NASDAQ: AVBP
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Zhengbin Yao Ph.D.
- Employees
- 77
- Headquarters
- 18 Campus Boulevard, Newtown Square, PA, United States
- Phone
- 628 277 4836
- Website
- arrivent.com
- IPO year
- 2024
- Market cap
- $544.13M
- SEC CIK
- 0001868279
- Latest annual report
- 10-K · Mar 5, 2026
Companies similar to ArriVent BioPharma
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CBIOCrescent Biopharma Inc. | 13.00 | +0.70% | $543.21M | vs AVBP |
| ACRSAclaris Therapeutics Inc. | 3.44 | -1.71% | $545.63M | vs AVBP |
| CLYMClimb Bio Inc. | 9.19 | -0.97% | $539.80M | vs AVBP |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs AVBP |
| BCAXBicara Therapeutics Inc. | 8.44 | -7.46% | $560.31M | vs AVBP |
| GERNGeron Corporation | 0.8707 | -4.63% | $560.94M | vs AVBP |
| ZVRAZevra Therapeutics Inc. | 8.76 | -3.42% | $521.26M | vs AVBP |
| ALMSAlumis Inc. | 3.96 | -8.54% | $514.09M | vs AVBP |